Pharmaceutical - AstraZeneca


Current filters:


Popular Filters

126 to 150 of 314 results

Is downgrade cycle levelling off a signal to buy AstraZeneca stock?


Anglo-Swedish drug major AstraZeneca (LSE: AZN) shares have been weak, as defensive stocks retrench from…


AstraZeneca gains rights to Merck ovarian cancer candidate


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US pharma giant Merck & Co (NYSE: MRK) this morning…

AstraZenecaLicensingMerck & CoMK-1775OncologyPharmaceutical

Generic risk to GSK's Advair prompts buy recommendation from analysts


Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

AstraZeneca's starts olaparib in Ph III for ovarian cancer


Anglo-Swedish drug major AstraZeneca (LSE: AZN) says it has enrolled the first patient in the Phase III…

AstraZenecaMarkets & MarketingMyriad GeneticsolaparibOncologyPharmaceuticalResearch

Onglyza meets primary safety endpoint in SAVOR CV outcomes trial


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb (NYSE: MBY) today…

AstraZenecaBristol-Myers SquibbCardio-vascularDermatologicalsOnglyzaPharmaceuticalResearch

Rigel shares fall as asthma compound fails to meet primary endpoint


Shares of USA-based Rigel Pharmaceuticals (Nasdaq: RIGL) fell 10% to $3.27 in morning trading yesterday…

AstraZenecafostamatinibNorth AmericaPharmaceuticalResearchRespiratory and PulmonaryRigel Pharmaceuticals

AstraZeneca nabs Amplimmune for $500 million


In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Nektar hedges bets on deal with AstraZeneca


Along with presenting second-quarter financial results, Howard Robin, president and chief executive of…

AstraZenecaFinancialGastro-intestinalsLicensingnaloxegolNektar TherapeuticsPharmaceutical

Growth drivers for China's type 2 diabetes market


The type 2 diabetes therapeutic market in China, the third largest after the USA and Japan, will grow…

Asia-PacificAstraZenecaBristol-Myers SquibbByettaDiabetesGalvusJanuviaMarkets & MarketingMerck & CoNovartisNovo NordiskOnglyzaPharmaceuticalVictoza

AstraZeneca records fall in 2nd-qtr revenue but 21% rise in China sales


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reported second-quarter 2013 financial results with…


Boehringer Ingelheim's Gilotrif could be leading therapy if it overcomes concerns, says GlobalData


Family-owned German drug major Boehringer Ingelheim could face "significant challenges" over its first-line…

AstraZenecaBoehringer IngelheimEuropeGilotrifIressaMarkets & MarketingOncologyPharmaceuticalRocheTarceva

Another senior departure at AstraZeneca


In yet another senior executive departure at Anglo-Swedish drug major AstraZeneca (LSE: AZN), Simon Lowth,…


AstraZeneca target Omthera files for US approval of Epanova


Emerging US specialty pharmaceutical company Omthera Pharmaceuticals (Nasdaq: OMTH) today (July 9) announced…

AstraZenecaCardio-vascularCrestorEpanovaOmthera PharmaceuticalsPharmaceutical

AstraZeneca in oncology partnerships with University of Cambridge, Cancer Research UK and Blackfield


Anglo-Swedish drug major AstraZeneca (LSE: AZN) has reached agreement with the University of Cambridge…

AstraZenecaBlackfieldBoehringer IngelheimJanssenMerck KGaAolaparibOncologyPharmaceuticalResearch

Largely negative views from Germany's IQWiG on AstraZeneca's Caprelsa in thyroid cancer


In a new benefit assessment, the German Institute for Quality and Efficiency in Health Care (IQWiG) has…


Mixed results for AstraZeneca/B-MS' Onglyza; Newron's safinamide does well in PD


Anglo-Swedish drug major AstraZeneca (LSE: AZN) and US partner Bristol-Myers Squibb have announced mixed…

AstraZenecaBristol-Myers SquibbDiabetesNeurologicalNewron PharmaOnglyzaPharmaceuticalResearchsafinamideZambon

AstraZeneca unit links with NGM Biopharma on diabetes and obesity research


Anglo-Swedish drug major AstraZeneca's (LSE: AZN) US biologics R&D subsidiary MedImmune has entered into…

AstraZenecaBiotechnologyDiabetesLicensingMedImmuneMetabolicsNGM BiopharmaceuticalsPharmaceuticalResearch

New Zealand to fund AstraZeneca's Brilinta for acute coronary syndromes


New Zealand's Pharmaceutical Management Agency, PHARMAC, says it has reached an agreement with the local…


AstraZeneca to pay up to $1.15 billion to acquire Pearl Therapeutics


In a further "strategic" bolt-on acquisition for Anglo-Swedish drug major AstraZeneca (LSE: AZN) in less…

AstraZenecaMergers & AcquisitionsPearl TherapeuticsPharmaceuticalPT003Respiratory and Pulmonary

126 to 150 of 314 results

Back to top